We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Partnership to Develop Injectable Tracer for Diagnosing, Tumor Surgery

By HospiMedica International staff writers
Posted on 06 Apr 2011
Five French partners are developing an injectable tracer that can provide both nuclear imaging in the preoperative evaluation of tumors and optical imaging during ablation or biopsy. More...


CEA-Leti (Grenoble, France) and three other French partners reported that the three-year Nano-ENO project is developing a specific tracer using a patented organic nanocarrier (Lipidot). To improve its targeting capacities, a peptide molecule that recognizes specific types of cancer will also be grafted to the Lipidots. CEA-Leti conducts research and develops nanoelectronics and technology for healthcare. The Nano-Eno project includes Advanced Accelerator Applications (Saint-Genis-Pouilly, France), Fluoptics (Grenoble, France), and VetAgro Sup (Marcy-l'Etoile, France), as well as Frédéric Joliot Hospital (Orsay, France).

When treating cancer, clinicians utilize several diagnostic tools and surgical aids, including positron emission tomography (PET) scan and fluorescence imaging. A PET scan is a nuclear imaging technology that allows radiologists to measure the metabolic activity of an organ by injecting a radiotracer and then examining the gamma rays that are emitted as the tracer disintegrates.

Fluorescence imaging is a comparatively new technology that combines the use of a florescent tracer with near-infrared spectroscopy (NIRS). The resulting real-time images help surgeons obtain cleaner margins during surgery and therefore reduce the risk of recurrence.

The nuclear imaging markers used in a PET scan help provide high-resolution images, while optical contrast agents facilitate the identification of tumor cells in real-time. Combining these imaging technologies makes it possible to confirm that the tumors being operated on correspond to the tumors identified in the preoperative studies. It also allows for a more thorough procedure to be performed with reduced overall surgical time; not only can the surgeon perform more rapidly and with greater precision, but the entire operation is streamlined, allowing for a more efficient use of operating rooms and surgical staff.

This project will receive support from the Cancéropôle Lyon Auvergne Rhône Alpes (CLARA; France) Preuve de Concept (Proof of Concept) initiative for three years.

CEA is a French government-funded technologic research organization. A prominent player in the European research area, it is involved in setting up collaborative projects with many partners worldwide. The CEA is based in 10 research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France, and Burgundy.

Related Links:

CEA-Leti



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.